Jul 1, 2025 | Benefits preservation, Diabetes, GLP-1s, MedBen Rx, Ozempic, Rebates, Specialty Drugs, Spread Pricing, Transparency, Wegovy, Weight loss, Weight loss drugs
The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a...
Jun 16, 2025 | Drug costs, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs
A recent Statista article examines the disparity in prescription drug spending across countries. The Organisation for Economic Co-operation and Development (OECD) ranks the United States highest in average spending, at $1,218 per resident – over $200 more than...
May 19, 2025 | Biosimilar, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
May 5, 2025 | Legislation, News, Pharmacies, Pharmacy Benefits Manager (PBM), State legislation
On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...
Apr 21, 2025 | Biosimilar, Cost Savings, Drug costs, Humira, Rx Costs, Savings, Stelara
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
